MA54051A - Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations - Google Patents
Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisationsInfo
- Publication number
- MA54051A MA54051A MA054051A MA54051A MA54051A MA 54051 A MA54051 A MA 54051A MA 054051 A MA054051 A MA 054051A MA 54051 A MA54051 A MA 54051A MA 54051 A MA54051 A MA 54051A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- sulfonamide derivatives
- pyridinyl sulfonamide
- pyridinyl
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203196 | 2018-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54051A true MA54051A (fr) | 2022-02-09 |
Family
ID=64082994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054051A MA54051A (fr) | 2018-10-29 | 2019-10-24 | Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20210361637A1 (fr) |
| EP (1) | EP3873600B9 (fr) |
| JP (1) | JP7317109B2 (fr) |
| KR (1) | KR20210084537A (fr) |
| CN (1) | CN112955215B (fr) |
| AU (1) | AU2019373306A1 (fr) |
| BR (1) | BR112021004635A2 (fr) |
| CA (1) | CA3112510A1 (fr) |
| CL (1) | CL2021000839A1 (fr) |
| CO (1) | CO2021005509A2 (fr) |
| CR (1) | CR20210216A (fr) |
| DK (1) | DK3873600T5 (fr) |
| DO (1) | DOP2021000068A (fr) |
| EA (1) | EA202191114A1 (fr) |
| EC (1) | ECSP21030482A (fr) |
| ES (1) | ES2967359T3 (fr) |
| FI (1) | FI3873600T3 (fr) |
| HR (1) | HRP20231608T1 (fr) |
| HU (1) | HUE064995T2 (fr) |
| IL (1) | IL282428A (fr) |
| LT (1) | LT3873600T (fr) |
| MA (1) | MA54051A (fr) |
| MX (1) | MX2021004940A (fr) |
| PE (1) | PE20211467A1 (fr) |
| PL (1) | PL3873600T3 (fr) |
| PT (1) | PT3873600T (fr) |
| RS (1) | RS64963B1 (fr) |
| SA (1) | SA521421755B1 (fr) |
| SG (1) | SG11202102440SA (fr) |
| SI (1) | SI3873600T1 (fr) |
| WO (1) | WO2020089026A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873599B1 (fr) * | 2018-10-29 | 2023-09-27 | Boehringer Ingelheim International GmbH | Dérivés de pyridinyl-sulfonamide, compositions pharmaceutiques et utilisations associées |
| CA3150108A1 (fr) | 2019-09-13 | 2021-03-18 | Neelu Kaila | Antagonistes de hpk1 et leurs utilisations |
| CN114621243B (zh) * | 2020-12-14 | 2024-03-01 | 上海拓界生物医药科技有限公司 | 一种磺酰胺类衍生物及其用途 |
| CN114621189B (zh) * | 2020-12-14 | 2024-01-02 | 上海拓界生物医药科技有限公司 | 一种内酰胺类衍生物及其用途 |
| CN114621190B (zh) * | 2020-12-14 | 2023-12-05 | 上海拓界生物医药科技有限公司 | 一种烯丙基胺类衍生物及其用途 |
| WO2022187856A1 (fr) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Antagonistes de hpk1 et leurs utilisations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69710921T2 (de) | 1996-12-19 | 2002-09-19 | Aventis Pharmaceuticals Inc., Bridgewater | Heterocyclische substituierte pyrrolidinamid-derivate |
| CA2671984A1 (fr) | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | Nouveaux derives pyridazines a activite antagoniste du recepteur mch et medicaments comprenant ces composes |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| RS57086B1 (sr) | 2012-05-02 | 2018-06-29 | Boehringer Ingelheim Int | Supstituisani 3-haloalilamin inhibitori ssao i njihova primena |
| SG11201809687TA (en) * | 2016-05-12 | 2018-11-29 | Boehringer Ingelheim Int | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors |
| WO2018027892A1 (fr) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Inhibiteurs de ssao à base d'amino pyrimidine |
| WO2018148856A1 (fr) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Composés de diazaspirodécanyl-pyrimidine utiles en tant qu'inhibiteurs de ssao |
| EP3873599B1 (fr) * | 2018-10-29 | 2023-09-27 | Boehringer Ingelheim International GmbH | Dérivés de pyridinyl-sulfonamide, compositions pharmaceutiques et utilisations associées |
-
2019
- 2019-10-24 PT PT197949704T patent/PT3873600T/pt unknown
- 2019-10-24 PE PE2021000602A patent/PE20211467A1/es unknown
- 2019-10-24 AU AU2019373306A patent/AU2019373306A1/en active Pending
- 2019-10-24 RS RS20231203A patent/RS64963B1/sr unknown
- 2019-10-24 MA MA054051A patent/MA54051A/fr unknown
- 2019-10-24 HU HUE19794970A patent/HUE064995T2/hu unknown
- 2019-10-24 KR KR1020217015606A patent/KR20210084537A/ko unknown
- 2019-10-24 CR CR20210216A patent/CR20210216A/es unknown
- 2019-10-24 FI FIEP19794970.4T patent/FI3873600T3/fi active
- 2019-10-24 HR HRP20231608TT patent/HRP20231608T1/hr unknown
- 2019-10-24 JP JP2021523407A patent/JP7317109B2/ja active Active
- 2019-10-24 CA CA3112510A patent/CA3112510A1/fr active Pending
- 2019-10-24 EP EP19794970.4A patent/EP3873600B9/fr active Active
- 2019-10-24 LT LTEPPCT/EP2019/078992T patent/LT3873600T/lt unknown
- 2019-10-24 MX MX2021004940A patent/MX2021004940A/es unknown
- 2019-10-24 SG SG11202102440SA patent/SG11202102440SA/en unknown
- 2019-10-24 BR BR112021004635-6A patent/BR112021004635A2/pt unknown
- 2019-10-24 PL PL19794970.4T patent/PL3873600T3/pl unknown
- 2019-10-24 CN CN201980071238.4A patent/CN112955215B/zh active Active
- 2019-10-24 EA EA202191114A patent/EA202191114A1/ru unknown
- 2019-10-24 WO PCT/EP2019/078992 patent/WO2020089026A1/fr active Application Filing
- 2019-10-24 SI SI201930672T patent/SI3873600T1/sl unknown
- 2019-10-24 ES ES19794970T patent/ES2967359T3/es active Active
- 2019-10-24 DK DK19794970.4T patent/DK3873600T5/da active
- 2019-10-24 US US17/285,918 patent/US20210361637A1/en active Pending
-
2021
- 2021-04-05 CL CL2021000839A patent/CL2021000839A1/es unknown
- 2021-04-14 SA SA521421755A patent/SA521421755B1/ar unknown
- 2021-04-16 DO DO2021000068A patent/DOP2021000068A/es unknown
- 2021-04-19 IL IL282428A patent/IL282428A/en unknown
- 2021-04-27 CO CONC2021/0005509A patent/CO2021005509A2/es unknown
- 2021-04-28 EC ECSENADI202130482A patent/ECSP21030482A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54051A (fr) | Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations | |
| MA49952A (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| MA52483A (fr) | Dérivés de gip et leurs utilisations | |
| MA52411A (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA43815A (fr) | Stéroïdes neuroactifs, compositions, et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA50413A (fr) | Dérivés de benzimidazole et leurs utilisations | |
| MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| MA52648A (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| MA52092A (fr) | Composés et leurs utilisations | |
| MA52094A (fr) | Anticorps anti-il-27 et leurs utilisations | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| MA54469A (fr) | Anticorps anti-il-27 et leurs utilisations | |
| MA52235A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA52976A (fr) | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations | |
| MA54455A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA52977A (fr) | Composés de cyanotriazole et leurs utilisations | |
| MA52626A (fr) | Anticorps anti-cd63, conjugués et leurs utilisations | |
| MA45718A (fr) | Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées |